HCW’s T-Cell Engager Sees Remarkable Primate Study Results
In preclinical testing, a subcutaneously administered, tissue factor–targeting T‑cell engager from HCW Biologics was well tolerated in non‑human primates...
Jon Napitupulu
Biosplice Doses First Patient in AML/MDS Clinical Trial
Biosplice has initiated dosing in an NCI-sponsored Phase 1 study of cirtuvivint in relapsed/refractory AML and MDS, testing the...
Apogee Reveals New APG777 Atopic Dermatitis Phase 2 Data
Apogee’s Phase 2 APEX trial of APG777 in moderate-to-severe atopic dermatitis met its primary and secondary endpoints at 16...
Maze’s MZE782 Shows Positive Results for PKU, CKD in Trial
In a randomized, placebo-controlled Phase 1 study in 112 healthy adults, Maze’s SLC6A19 inhibitor MZE782 produced large, dose-dependent pharmacodynamic...
New Dubstent Trial Seeks Better PCI Outcomes for Diabetes
A 120-patient randomized trial in Ireland will compare a hybrid percutaneous coronary intervention strategy—drug-coated balloon angioplasty followed by drug-eluting...
First Patient Dosed in New Glioblastoma/Pancreatic Study
RadioMedix and Vect-Horus have dosed the first patient in an exploratory IND evaluating 203Pb-RMX-VH-PIB, an LDL receptor–targeted SPECT imaging...
Bioxodes Reports Breakthrough Phase 2a Data for Stroke Drug
Primary safety was met in a 23‑patient Phase 2a study of BIOX-101 for intracerebral hemorrhage, with all treated patients...
Dewpoint Closes Series D for Gastric Cancer Clinical Trial
Dewpoint Therapeutics has closed an undisclosed Series D that extends its runway into early 2027 and funds first-in-human development...
Vaxart Reports Positive Phase 1 Data for Norovirus Pill
Vaxart’s second-generation oral norovirus constructs drove a 25-fold increase in GII.4 fecal IgA and a 10-fold increase in GI.1...
New daraxorasib Data Supports Phase 3 Pancreatic Cancer Trial
In second-line metastatic PDAC, daraxonrasib monotherapy at 300 mg QD delivered a confirmed ORR of 35% in KRAS G12X...